|
1
|
National Cancer Institute: SEER stat fact
sheets, pancreas. http://seer.cancer.gov/statfacts/html/pancreas.html.
Accessed April 15, 2016.
|
|
2
|
Vogelstein B, Papadopoulos N, Velculescu
VE, Zhou S, Diaz LA Jr and Kinzler KW: Cancer genome landscapes.
Science. 339:1546–1558. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wood LD and Hruban RH: Pathology and
molecular genetics of pancreatic neoplasms. Cancer J. 18:492–501.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Almoguera C, Shibata D, Forrester K,
Martin J, Arnheim N and Perucho M: Most human carcinomas of the
exocrine pancreas contain mutant c-K-ras genes. Cell. 53:549–554.
1988. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Smit VT, Boot AJ, Smits AM, Fleuren GJ,
Cornelisse CJ and Bos JL: KRAS codon 12 mutations occur very
frequently in pancreatic adenocarcinomas. Nucleic Acids Res.
16:7773–7782. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kawaguchi Y, Cooper B, Gannon M, Ray M,
MacDonald RJ and Wright CV: The role of the transcriptional
regulator Ptf1a in converting intestinal to pancreatic progenitors.
Nat Genet. 32:128–134. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hingorani SR, Petricoin EF, Maitra A,
Rajapakse V, King C, Jacobetz MA, Ross S, Conrads TP, Veenstra TD,
Hitt BA, et al: Preinvasive and invasive ductal pancreatic cancer
and its early detection in the mouse. Cancer Cell. 4:437–450. 2003.
View Article : Google Scholar
|
|
8
|
Olive KP and Tuveson DA: The use of
targeted mouse models for preclinical testing of novel cancer
therapeutics. Clin Cancer Res. 12:5277–5287. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Morris JP IV, Wang SC and Hebrok M: KRAS,
Hedgehog, Wnt and the twisted developmental biology of pancreatic
ductal adenocarcinoma. Nat Rev Cancer. 10:683–695. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Aguirre AJ, Bardeesy N, Sinha M, Lopez L,
Tuveson DA, Horner J, Redston MS and DePinho RA: Activated KRAS and
Ink4a/Arf deficiency cooperate to produce metastatic pancreatic
ductal adenocarcinoma. Genes Dev. 17:3112–3126. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hingorani SR, Wang L, Multani AS, Combs C,
Deramaudt TB, Hruban RH, Rustgi AK, Chang S and Tuveson DA:
Trp53R172H and KRASG12D cooperate to promote chromosomal
instability and widely metastatic pancreatic ductal adenocarcinoma
in mice. Cancer Cell. 7:469–483. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Singh M, Lima A, Molina R, Hamilton P,
Clermont AC, Devasthali V, Thompson JD, Cheng JH, Bou Reslan H, Ho
CC, et al: Assessing therapeutic responses in KRAS mutant cancers
using genetically engineered mouse models. Nat Biotechnol.
28:585–593. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
13
|
Carrière C, Young AL, Gunn JR, Longnecker
DS and Korc M: Acute pancreatitis accelerates initiation and
progression to pancreatic cancer in mice expressing oncogenic KRAS
in the nestin cell lineage. PLoS One. 6:e277252011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Clark CE, Hingorani SR, Mick R, Combs C,
Tuveson DA and Vonderheide RH: Dynamics of the immune reaction to
pancreatic cancer from inception to invasion. Cancer Res.
67:9518–9527. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Won JH, Zhang Y, Ji B, Logsdon CD and Yule
DI: Phenotypic changes in mouse pancreatic stellate cell Ca2+
signaling events following activation in culture and in a disease
model of pancreatitis. Mol Biol Cell. 22:421–436. 2011. View Article : Google Scholar :
|
|
16
|
Erkan M, Adler G, Apte MV, Bachem MG,
Buchholz M, Detlefsen S, Esposito I, Friess H, Gress TM, Habisch
HJ, et al: StellaTUM: Current consensus and discussion on
pancreatic stellate cell research. Gut. 61:172–178. 2012.
View Article : Google Scholar
|
|
17
|
Jacobetz MA, Chan DS, Neesse A, Bapiro TE,
Cook N, Frese KK, Feig C, Nakagawa T, Caldwell ME, Zecchini HI, et
al: Hyaluronan impairs vascular function and drug delivery in a
mouse model of pancreatic cancer. Gut. 62:112–120. 2013. View Article : Google Scholar :
|
|
18
|
Provenzano PP, Cuevas C, Chang AE, Goel
VK, Von Hoff DD and Hingorani SR: Enzymatic targeting of the stroma
ablates physical barriers to treatment of pancreatic ductal
adenocarcinoma. Cancer Cell. 21:418–429. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Charo C, Hwang RF, Arumugam T, Hwang R,
Yang P, Dubois RN, Menter DG, Logsdon CD and Ramachandran V:
Prostaglandin E2 regulates pancreatic stellate cell activity via
the EP4 receptor. Pancreas. 42:467–474. 2013. View Article : Google Scholar :
|
|
20
|
Thayer SP, di Magliano MP, Heiser PW,
Nielsen CM, Roberts DJ, Lauwers GY, Qi YP, Gysin S, Fernández-del
Castillo C, Yajnik V, et al: Hedgehog is an early and late mediator
of pancreatic cancer tumorigenesis. Nature. 425:851–856. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Berman DM, Karhadkar SS, Maitra A, Montes
De Oca R, Gerstenblith MR, Briggs K, Parker AR, Shimada Y, Eshleman
JR, Watkins DN and Beachy PA: Widespread requirement for hedgehog
ligand stimulation in growth of digestive tract tumours. Nature.
425:846–851. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yauch RL, Gould SE, Scales SJ, Tang T,
Tian H, Ahn CP, Marshall D, Fu L, Januario T, Kallop D, et al: A
paracrine requirement for hedgehog signalling in cancer. Nature.
455:406–410. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Olive KP, Jacobetz MA, Davidson CJ,
Gopinathan A, McIntyre D, Honess D, Madhu B, Goldgraben MA,
Caldwell ME, Allard D, et al: Inhibition of hedgehog signaling
enhances delivery of chemotherapy in a mouse model of pancreatic
cancer. Science. 324:1457–1461. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lesina M, Kurkowski MU, Ludes K, Rose-John
S, Treiber M, Klöppel G, Yoshimura A, Reindl W, Sipos B, Akira S,
et al: Stat3/Socs3 activation by IL-6 transsignaling promotes
progression of pancreatic intraepithelial neoplasia and development
of pancreatic cancer. Cancer Cell. 19:456–469. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Chang DZ, Ma Y, Ji B, Wang H, Deng D, Liu
Y, Abbruzzese JL, Liu YJ, Logsdon CD and Hwu P: Mast cells in tumor
micro-environment promotes the in vivo growth of pancreatic ductal
adenocarcinoma. Clin Cancer Res. 17:7015–7023. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Pylayeva-Gupta Y, Lee KE, Hajdu CH, Miller
G and Bar-Sagi D: Oncogenic KRAS-induced GM-CSF production promotes
the development of pancreatic neoplasia. Cancer Cell. 21:836–847.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Bayne LJ, Beatty GL, Jhala N, Clark CE,
Rhim AD, Stanger BZ and Vonderheide RH: Tumor-derived
granulocyte-macrophage colony-stimulating factor regulates myeloid
inflammation and T cell immunity in pancreatic cancer. Cancer Cell.
21:822–835. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yadav D and Lowenfels AB: The epidemiology
of pancreatitis and pancreatic cancer. Gastroenterology.
144:1252–1261. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Pylayeva-Gupta Y, Grabocka E and Bar-Sagi
D: RAS oncogenes: Weaving a tumorigenic web. Nat Rev Cancer.
11:761–774. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Steele CW, Jamieson NB, Evans TR, McKay
CJ, Sansom OJ, Morton JP and Carter CR: Exploiting inflammation for
therapeutic gain in pancreatic cancer. Br J Cancer. 108:997–1003.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Guerra C, Schuhmacher AJ, Cañamero M,
Grippo PJ, Verdaguer L, Pérez-Gallego L, Dubus P, Sandgren EP and
Barbacid M: Chronic pancreatitis is essential for induction of
pancreatic ductal adenocarcinoma by K-Ras oncogenes in adult mice.
Cancer Cell. 11:291–302. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Collins MA, Bednar F, Zhang Y, Brisset JC,
Galbán S, Galbán CJ, Rakshit S, Flannagan KS, Adsay NV and Pasca di
Magliano M: Oncogenic Kras is required for both the initiation and
maintenance of pancreatic cancer in mice. J Clin Invest.
122:639–653. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Warburg O: On the origin of cancer cells.
Science. 123:309–314. 1956. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Feldmann G, Beaty R, Hruban RH and Maitra
A: Molecular genetics of pancreatic intraepithelial neoplasia. J
Hepatobiliary Pancreat Surg. 14:224–232. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Gaglio D, Metallo CM, Gameiro PA, Hiller
K, Danna LS, Balestrieri C, Alberghina L, Stephanopoulos G and
Chiaradonna F: Oncogenic K-Ras decouples glucose and glutamine
metabolism to support cancer cell growth. Mol Syst Biol. 7:5232011.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Dell'Antone P: Energy metabolism in cancer
cells: How to explain the Warburg and Crabtree effects? Med
Hypotheses. 79:388–392. 2012. View Article : Google Scholar
|
|
37
|
Bryant KL, Mancias JD, Kimmelman AC and
Der CJ: KRAS: Feeding pancreatic cancer proliferation. Trends
Biochem Sci. 39:91–100. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Ying H, Kimmelman AC, Lyssiotis CA, Hua S,
Chu GC, Fletcher-Sananikone E, Locasale JW, Son J, Zhang H, Coloff
JL, et al: Oncogenic Kras maintains pancreatic tumors through
regulation of anabolic glucose metabolism. Cell. 149:656–670. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Wise DR, DeBerardinis RJ, Mancuso A, Sayed
N, Zhang XY, Pfeiffer HK, Nissim I, Daikhin E, Yudkoff M, McMahon
SB and Thompson CB: Myc regulates a transcriptional program that
stimulates mitochondrial glutaminolysis and leads to glutamine
addiction. Proc Natl Acad Sci USA. 105:18782–18787. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Son J, Lyssiotis CA, Ying H, Wang X, Hua
S, Ligorio M, Perera RM, Ferrone CR, Mullarky E, Shyh-Chang N, et
al: Glutamine supports pancreatic cancer growth through a
KRAS-regulated metabolic pathway. Nature. 496:101–105. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Rosenfeldt MT, O'Prey J, Morton JP, Nixon
C, MacKay G, Mrowinska A, Au A, Rai TS, Zheng L, Ridgway R, et al:
p53 status determines the role of autophagy in pancreatic tumour
development. Nature. 504:296–300. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Kamphorst JJ, Cross JR, Fan J, de
Stanchina E, Mathew R, White EP, Thompson CB and Rabinowitz JD:
Hypoxic and Ras-transformed cells support growth by scavenging
unsaturated fatty acids from lysophospholipids. Proc Natl Acad Sci
USA. 110:8882–8887. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Commisso C, Davidson SM, Soydaner-Azeloglu
RG, Parker SJ, Kamphorst JJ, Hackett S, Grabocka E, Nofal M, Drebin
JA, Thompson CB, et al: Macropinocytosis of protein is an amino
acid supply route in Ras-transformed cells. Nature. 497:633–637.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Neesse A, Michl P, Frese KK, Feig C, Cook
N, Jacobetz MA, Lolkema MP, Buchholz M, Olive KP, Gress TM and
Tuveson DA: Stromal biology and therapy in pancreatic cancer. Gut.
60:861–868. 2011. View Article : Google Scholar
|
|
45
|
Zhu L, Shi G, Schmidt CM, Hruban RH and
Konieczny SF: Acinar cells contribute to the molecular
heterogeneity of pancreatic intraepithelial neoplasia. Am J Pathol.
171:263–273. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Mazur PK and Siveke JT: Genetically
engineered mouse models of pancreatic cancer: Unravelling tumour
biology and progressin translational oncology. Gut. 61:1488–1500.
2012. View Article : Google Scholar
|
|
47
|
Pérez-Mancera PA, Guerra C, Barbacid M and
Tuveson DA: What we have learned about pancreatic cancer from mouse
models. Gastroenterology. 142:1079–1092. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Qiu W and Su GH: Challenges and advances
in mouse modeling for human pancreatic tumorigenesis and
metastasis. Cancer Metastasis Rev. 32:83–107. 2013. View Article : Google Scholar
|
|
49
|
Westphalen CB and Olive KP: Genetically
engineered mouse models of pancreatic cancer. Cancer J. 18:502–510.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Hanlon L, Avila JL, Demarest RM, Troutman
S, Allen M, Ratti F, Rustgi AK, Stanger BZ, Radtke F, Adsay V, et
al: Notch1 functions as a tumor suppressor in a model of
K-ras-induced pancreatic ductal adenocarcinoma. Cancer Res.
70:4280–4286. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Mazur PK, Einwächter H, Lee M, Sipos B,
Nakhai H, Rad R, Zimber-Strobl U, Strobl LJ, Radtke F, Klöppel G,
et al: Notch2 is required for progression of pancreatic
intraepithelial neoplasia and development of pancreatic ductal
adenocarcinoma. Proc Natl Acad Sci USA. 107:13438–13443. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Guerra C, Collado M, Navas C, Schuhmacher
AJ, Hernández-Porras I, Cañamero M, Rodriguez-Justo M, Serrano M
and Barbacid M: Pancreatitis-induced inflammation contributes to
pancreatic cancer by inhibiting oncogene induced senescence. Cancer
Cell. 19:728–739. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Jones S, Zhang X, Parsons DW, Lin JC,
Leary RJ, Angenendt P, Mankoo P, Carter H, Kamiyama H, Jimeno A, et
al: Core signaling pathways in human pancreatic cancers revealed by
global genomic analyses. Science. 321:1801–1806. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Collisson EA, Trejo CL, Silva JM, Gu S,
Korkola JE, Heiser LM, Charles RP, Rabinovich BA, Hann B, Dankort
D, et al: A central role for RAF-MEK-ERK signaling in the genesis
of pancreatic ductal adenocarcinoma. Cancer Discov. 2:685–693.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Hruban RH, Canto M, Goggins M, Schulick R
and Klein AP: Update on familial pancreatic cancer. Adv Surg.
44:293–311. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Skoulidis F, Cassidy LD, Pisupati V,
Jonasson JG, Bjarnason H, Eyfjord JE, Karreth FA, Lim M, Barber LM,
Clatworthy SA, et al: Germline Brca2 heterozygosity promotes Kras
(G12D)-driven carcinogenesis in a murine model of familial
pancreatic cancer. Cancer Cell. 18:499–509. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Rowley M, Ohashi A, Mondal G, Mills L,
Yang L, Zhang L, Sundsbak R, Shapiro V, Muders MH, Smyrk T and
Couch FJ: Inactivation of Brca2 promotes Trp53-associated but
inhibits KrasG12D-dependent pancreatic cancer development in mice.
Gastroenterology. 140:1303–1313. e1–e3. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Morton JP, Jamieson NB, Karim SA, Athineos
D, Ridgway RA, Nixon C, McKay CJ, Carter R, Brunton VG, Frame MC,
et al: LKB1 haploinsufficiency cooperates with Kras to promote
pancreatic cancer through suppression of p21-dependent growth
arrest. Gastroenterology. 139:586–597. e1–e6. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Hanahan D: Heritable formation of
pancreatic beta-cell tumours in transgenic mice expressing
recombinant insulin/simian virus 40 oncogenes. Nature. 315:115–122.
1985. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Bardeesy N, Cheng KH, Berger JH, Chu GC,
Pahler J, Olson P, Hezel AF, Horner J, Lauwers GY, Hanahan D and
DePinho RA: Smad4 is dispensable for normal pancreas development
yet critical in progression and tumor biology of pancreas cancer.
Genes Dev. 20:3130–3146. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Izeradjene K, Combs C, Best M, Gopinathan
A, Wagner A, Grady WM, Deng CX, Hruban RH, Adsay NV, Tuveson DA and
Hingorani SR: Kras (G12D) and Smad4/Dpc4 haploinsufficiency
cooperate to induce mucinous cystic neoplasms and invasive
adenocarcinoma of the pancreas. Cancer Cell. 11:229–243. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Siveke JT, Lubeseder-Martellato C, Lee M,
Mazur PK, Nakhai H, Radtke F and Schmid RM: Notch signaling is
required for exocrine regeneration after acute pancreatitis.
Gastroenterology. 134:544–555. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Vincent DF, Yan KP, Treilleux I, Gay F,
Arfi V, Kaniewski B, Marie JC, Lepinasse F, Martel S, Goddard-Leon
S, et al: Inactivation of TIF1gamma cooperates with Kras to induce
cystic tumors of the pancreas. PLoS Genet. 5:e10005752009.
View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Appels NM, Beijnen JH and Schellens JH:
Development of farnesyl transferase inhibitors: A review.
Oncologist. 10:565–578. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Kohl NE, Omer CA, Conner MW, Anthony NJ,
Davide JP, deSolms SJ, Giuliani EA, Gomez RP, Graham SL, Hamilton
K, et al: Inhibition of farnesyltransferase induces regression of
mammary and salivary carcinomas in ras transgenic mice. Nat Med.
1:792–797. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Whyte DB, Kirschmeier P, Hockenberry TN,
Nunez-Oliva I, James L, Catino JJ, Bishop WR and Pai JK: K- and
N-Ras are geranylgeranylated in cells treated with farnesyl protein
transferase inhibitors. J Biol Chem. 272:14459–14464. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Zimmermann G, Papke B, Ismail S, Vartak N,
Chandra A, Hoffmann M, Hahn SA, Triola G, Wittinghofer A, Bastiaens
PI and Waldmann H: Small molecule inhibition of the KRAS-PDEδ
interaction impairs oncogenic KRAS signalling. Nature. 497:638–642.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Chandra A, Grecco HE, Pisupati V, Perera
D, Cassidy L, Skoulidis F, Ismail SA, Hedberg C, Hanzal-Bayer M,
Venkitaraman AR, et al: The GDI-like solubilizing factor PDEδ
sustains the spatial organization and signalling of Ras family
proteins. Nat Cell Biol. 14:148–158. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Weisz B, Giehl K, Gana-Weisz M, Egozi Y,
Ben-Baruch G, Marciano D, Gierschik P and Kloog Y: A new functional
Ras antagonist inhibits human pancreatic tumor growth in nude mice.
Oncogene. 18:2579–2588. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Laheru D, Shah P, Rajeshkumar NV,
McAllister F, Taylor G, Goldsweig H, Le DT, Donehower R, Jimeno A,
Linden S, et al: Integrated preclinical and clinical development of
S-trans, trans-Farnesylthiosalicylic Acid (FTS, Salirasib) in
pancreatic cancer. Invest New Drugs. 30:2391–2399. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Patgiri A, Yadav KK, Arora PS and Bar-Sagi
D: An orthosteric inhibitor of the Ras-Sos interaction. Nat Chem
Biol. 7:585–587. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Eser S, Reiff N, Messer M, Seidler B,
Gottschalk K, Dobler M, Hieber M, Arbeiter A, Klein S, Kong B, et
al: Selective requirement of PI3K/PDK1 signaling for Kras
oncogene-driven pancreatic cell plasticity and cancer. Cancer Cell.
23:406–420. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Engelman JA: Targeting PI3K signalling in
cancer: Opportunities, challenges and limitations. Nat Rev Cancer.
9:550–562. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Shimizu T, Tolcher AW, Papadopoulos KP,
Beeram M, Rasco DW, Smith LS, Gunn S, Smetzer L, Mays TA, Kaiser B,
et al: The clinical effect of the dual-targeting strategy involving
PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced
cancer. Clin Cancer Res. 18:2316–2325. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Molina-Arcas M, Hancock DC, Sheridan C,
Kumar MS and Downward J: Coordinate direct input of both KRAS and
IGF1 receptor to activation of PI3 kinase in KRAS-mutant lung
cancer. Cancer Discov. 3:548–563. 2013. View Article : Google Scholar : PubMed/NCBI
|
